Prognostic impact of blood CTPC by NGF (vs BM MRD and sIF) on PFS of MM patients according to patient response to therapy. (A-B) Effect of PB CTPC, (D-E) BM MRD, (H) combination of both parameters, and (G) PB CTPC together with sIF status on PFS is displayed for (A, D, G) the entire MM cohort and (B, E, H) for sCR and CR patients, respectively. PFS curves of MM patients grouped according to (C) their sequential PB CTPC (^−/− or ^+/− vs ^−/+ and ^+/+), (F) sIF status, or (I) a combination of both, are shown. Overall, CTPC⁻ and MRD⁻ was defined as the absence of TPC in PB or BM by NGF, respectively, with a limit of detection of <2 × 10⁻⁶. CR, complete response; NR, not reached; PB, peripheral blood.